Biotech News

CVRx Announces Nomination of Michael Dale for Election to the Board of Directors

CVRx (CVRX)CVRx2026-04-20 20:30 ESTCompany update

MINNEAPOLIS, April 20, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX), a medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, announced today the nomination of Michael Dale to serve on its

Open original release

Related news

CVRXCVRx2026-05-27 20:30 EST

CVRx to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

CVRXCVRx2026-05-20 20:30 EST

CVRx to Present at the William Blair 46th Annual Growth Stock Conference

COOThe Cooper Companies2026-05-04 20:15 EST

CooperCompanies Appoints Paul Keel to its Board of Directors

TCMDTactile Systems Technology, Inc.2026-07-13 12:00 EST

Tactile Medical Enters Exclusive U.S. Distribution Agreement with ElastiMed for its MyoSleeve™ Wearable Compression Device for VA and DoD Patients

NAMSNewAmsterdam Pharma2026-07-01 12:00 EST

NewAmsterdam Pharma Announces Upcoming Presentations at the Alzheimer's Association International Conference (AAIC) 2026

MLYSMineralys Therapeutics2026-06-08 20:05 EST

Mineralys Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

NAMSNewAmsterdam Pharma2026-06-03 12:00 EST

NewAmsterdam Pharma Announces Upcoming Presentations at the National Lipid Association (NLA) 2026 Scientific Sessions

MNKDMannKind2026-06-03 10:05 EST

MannKind Enters Data-Rich Development Period with Completion of Randomization in Phase 1b INFLO-1 Study and Enrollment of First Patient in Phase 2 INFLO-2 Trial for Nintedanib DPI in Patients with IPF

TCMDTactile Systems Technology, Inc.2026-05-20 20:05 EST

Tactile Medical to Present at the William Blair 46th Annual Growth Stock Conference

XTNTXtant Medical2026-05-06 12:00 EST

Xtant Medical Expands Trivium™ Portfolio with the Commercial Launch of Trivium™ Shaped

View all latest news

CVRx

CVRx is a medical device company focused on neuromodulation therapies for heart failure and hypertension-related conditions. Its products aim to address cardiovascular disease through implanted device technology.

Recent company news

CVRXCVRx2026-05-27 20:30 EST

CVRx to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

CVRXCVRx2026-05-20 20:30 EST

CVRx to Present at the William Blair 46th Annual Growth Stock Conference

CVRXCVRx2026-05-14 12:00 EST

CVRx Announces Humana Medicare Advantage Coverage Policy for Barostim Therapy

CVRXCVRx2026-05-11 20:05 EST

CVRx Reports First Quarter 2026 Financial and Operating Results

CVRXCVRx2026-05-04 20:30 EST

CVRx Announces First Patient Enrollment in BENEFIT-HF, a Landmark Heart Failure Trial Evaluating Barostim in Significantly Expanded Population

Stock data

Close: 4.88 USD
Market cap: 144.09M USD
Exchange: NASDAQ
Sector: Biopharma
Location: United States